PFE · Full Picture

PFIZER INC — the full picture

Earnings window · 2026-07-14 to 2026-08-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Headcount / Restructuring · Restructuring & impairmentPriority 89
    +27.3% operating_income; 3 sources (news, press_release, sec_filing); 4 forward row(s); structured_verified
    Announces additional anticipated productivity enhancement savings of $2.5 billion expected to be realized from 2027 through 2029
  2. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 84
    -3.7% net_income; 3 sources (news, press_release, sec_filing); 7 forward row(s); structured_verified
    Innovent Biologics received a $650 million upfront payment and is eligible for up to $9.85 billion in development, regulatory and commercial milestone payments and up to double-digit royalties on sales of each licensed product if approved; transaction closed July 10, 2026
  3. Impairment Charges · Restructuring & impairmentPriority 81
    -68.0% operating_income (realized); structured_verified
    Other (income)/deductions—net unfavorable change of $3.0 billion in Q2 2026 and $2.9 billion for the first six months of 2026, primarily driven by intangible asset impairment charges, charges for certain legal matters, and increases in fair value of contingent consideration liabilities, partially offset by a net gain from sale of prior ViiV investment.
  4. Intangible Asset Impairments · UnclassifiedPriority 78
    -28.8% net_income (realized); quote_verified
    Reported Loss Per Share reflects $4.3 billion in Non-Cash Intangible Asset Impairments
  5. Gross Margin Drivers · Gross marginPriority 76
    -8.3% operating_income; 2 sources (press_release, sec_filing); 4 forward row(s); structured_verified
    Next phase of Manufacturing Optimization Program expected to deliver additional anticipated savings of approximately $1.5 billion through 2029 with one-time costs to achieve savings expected to be approximately $4.0 billion, ~60% non-cash and ~40% cash
  6. Revenue Performance and Mix · Revenue growth & mixPriority 76
    +20.3% revenue (realized); 3 sources (news, press_release, sec_filing); structured_verified
    Padcev QTD global revenues $667 million, up 23% operationally; YTD $1,258 million, up 30% operationally.
  7. Operating Cash Flow Trends · Cash flow generationPriority 74
    -24.3% operating_income (realized); structured_verified
    Loss from continuing operations before provision/(benefit) for taxes in the second quarter of 2026 was $653 million, compared to income of $3.0 billion in the second quarter of 2025.
  8. Operating Expense Trends · Operating expenses (SG&A)Priority 74
    +29.5% net_income (realized); 2 sources (press_release, sec_filing); 2 forward row(s); structured_verified
    Pfizer deployed $5.3 billion invested in internal research and development projects in the first six months of 2026
  9. Guidance and Outlook · Guidance & outlookPriority 71
    +2.8% revenue; 3 sources (news, press_release, sec_filing); 4 forward row(s); quote_verified
    Pfizer expects full-year 2026 revenue to total $60.5 billion to $62.5 billion, compared with a previous outlook of $59.5 billion to $62.5 billion.
  10. Litigation and Legal Risk · Litigation & settlementsPriority 71
    3 sources (news, press_release, sec_filing); 2 forward row(s); quote_verified
    Other (income)/deductions—net components for Q2 2026 included certain legal matters net of $842 million and certain asset impairments of $4,325 million
  11. Geographic Revenue Shift · Geographic mixPriority 70
    +400.0% revenue (realized); 2 sources (press_release, sec_filing); quote_verified
    Total International revenues for Second-Quarter 2026: $6,177 million, up 7% (or 3% operational) versus 2025
  12. COVID Product Demand Decline · Demand, orders & backlogPriority 63
    -10.8% revenue (realized); quote_verified
    Revised 2026 revenue expectation for COVID-19 products: down to approximately $4 billion from approximately $5 billion previously

Threads by pillar

Revenue & Demand Priority 86 · 8 threads

Costs & Margins Priority 97 · 9 threads

Capital & Balance Sheet Priority 86 · 5 threads

Strategy & Portfolio Priority 85 · 2 threads

Legal, Regulatory & Policy Priority 84 · 6 threads

Guidance & Outlook Priority 71 · 1 thread

Macro & Market Conditions Priority 62 · 1 thread

Unclassified Priority 90 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income+20.3%+91.5%-106.8%
revenue-0.8%+6.5%+407.1%
net_income-3.7%+3.7%+42.0%
assets-0.6%+0.6%—
cash-0.4%+0.4%+1.1%
liability-0.4%+0.4%—
margin——-1.4%